knowledge -WSS

knowledge

author：entertainment 2025-09-07 11:09:34 - browse：18

Aduhelm package — Jessica Rinaldi/The Boston Globe

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history.

Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s.

“When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Biogen CEO Christopher Viehbacher said in a statement. “Aduhelm was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： The nurse manager staffing crisis is hurting patients

WSS

JPM 2024: Nvidia claims we're in biological revolution. Are we?

Caregivers of transplant patients call for more support, training

Baltimore teen accused of firing into crowd during block party mass shooting

As Maui death toll rises, number of missing remains unclear

As JPM 2024 winds down, some health tech firms project optimism

HHS names first

knowledge

knowledge

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

Beware the threat of staffing cuts at the CDC

How to save PrEP access — and even expand it

The pain doctors face in trying to build their families

Peter Hotez and the public health issue of online harassment

As JPM 2024 winds down, some health tech firms project optimism

As demand for Covid shots wanes, Moderna seeks its next success

Liz Cheney makes 1st public comment since Trump's election interference indictments

Cancer drug shortages should be causing more outrage

Trump cancels press conference intended to dispute Georgia election interference charges

hotspot

Beware the threat of staffing cuts at the CDC

Caregivers of transplant patients call for more support, training

ProMED sees offers of support, but its future remains unclear

The boys, now 6, who are gene therapy’s ‘edge case’ problem

An interview with Robert F. Kennedy Jr. on vaccines

HHS names first

leisure time

leisure time

hotspot

leisure time